EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer

Patrick W Underwood, Samantha M Ruff, Timothy M Pawlik iD

Cells · 28.01.2024 · 13 (3) · 245

DOI: 10.3390/cells13030245 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 28.01.2024. Verfasst von Patrick W Underwood und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, 395 W. 12th Ave., Suite 670, Columbus, …. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 129-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic colorectal cancer remains a deadly malignancy and is the third leading cause of cancer-related death. The mainstay of treatment for metastatic colorectal cancer is chemotherapy, but unfortunately, even with recent progress, overall survival is still poor. Colorectal cancer is a heterogeneous disease, and the underlying genetic differences among tumors can define the behavior and prognosis of the disease. Given the limitations of cytotoxic chemotherapy, research has focused on developing targeted therapy based on molecular subtyping. Since the early 2000s, multiple targeted therapies have demonstrated efficacy in treating metastatic colorectal cancer and have received FDA approval. The epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and DNA mismatch repair pathways have demonstrated promising results for targeted therapies. As new gene mutations and proteins involved in the oncogenesis of metastatic colorectal cancer are identified, new targets will continue to emerge. We herein provide a summary of the updated literature regarding targeted therapies for patients with mCRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColonic NeoplasmsRectal NeoplasmsHumansVascular Endothelial Growth Factor AImmunotherapy

Stichwörter der Autor:innen

colorectal cancermolecular profilingpersonalized medicinetargeted therapy

Substanzen

Vascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, 395 W. 12th Ave., Suite 670, Columbus, OH 43210, USA.

ORCID-Profile: Timothy M Pawlik

Zitieren

APA

Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024). Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer. Cells, 13(3), 245. https://doi.org/10.3390/cells13030245

Vancouver

Underwood PW, Ruff SM, Pawlik TM. Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer. Cells. 2024;13(3):245. doi:10.3390/cells13030245

BibTeX
@article{Underwood2024,
  author = {Underwood, Patrick W and Ruff, Samantha M and Pawlik, Timothy M},
  title = {Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {3},
  pages = {245},
  doi = {10.3390/cells13030245}
}
Kostenlos starten →